NYSE:BVS Bioventus (BVS) Stock Price, News & Analysis $9.80 +0.19 (+1.98%) Closing price 04:00 PM EasternExtended Trading$9.63 -0.17 (-1.73%) As of 06:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends About Bioventus Stock (NYSE:BVS) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Bioventus alerts:Sign Up Key Stats Today's Range$9.52▼$10.0350-Day Range$8.76▼$11.0552-Week Range$3.90▼$14.38Volume394,469 shsAverage Volume421,012 shsMarket Capitalization$795.32 millionP/E RatioN/ADividend YieldN/APrice Target$15.00Consensus RatingModerate Buy Company OverviewBioventus Inc., a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain. Its surgical solutions comprise bone graft substitutes that increase bone formation to stimulate bone healing in spinal fusions and other orthopedic surgeries; and ultrasonic products used for precise bone cutting and sculpting, soft tissue management, and tissue debridement, in various surgeries, including minimally invasive applications. The company's product include, Osteoamp, an allograft-derived bone graft for bone grafting procedures; Exponent matrix for posterolateral spine procedures; Purebone for bone grafting procedures; Signafuse bone graft; Interfuse bone graft; Osteomatrix+ synthetic bone graft; Extractor for autologous cell and bone marrow extraction; reficio bone matrix; nexus ultrasonic surgical system; bonescalpel surgical solution; SonaStar for surgical procedures; and SonicOne ultrasonic cleansing and debridement system. The company's restorative therapies include a bone stimulation system and devices to help patients regain leg or hand function due to stroke, multiple sclerosis, or other central nervous system disorders. Its products include exogen, a bone healing system; L300 GO, a foot drop system; H200 rehabilitation system; Vector, a body weight support system; and Bioness integrated therapy system. It developing Talisman pulse generator and receiver for peripheral nerve stimulation. The company was founded in 2011 and is headquartered in Durham, North Carolina.Read More… Remove Ads Bioventus Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks66th Percentile Overall ScoreBVS MarketRank™: Bioventus scored higher than 66% of companies evaluated by MarketBeat, and ranked 355th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingBioventus has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBioventus has only been the subject of 2 research reports in the past 90 days.Read more about Bioventus' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings Growth12.20% Earnings GrowthEarnings for Bioventus are expected to grow by 12.20% in the coming year, from $0.41 to $0.46 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Bioventus is -16.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Bioventus is -16.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBioventus has a P/B Ratio of 3.50. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for BVS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBioventus does not currently pay a dividend.Dividend GrowthBioventus does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for BVS. News and Social Media2.5 / 5News Sentiment0.51 News SentimentBioventus has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.77 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Bioventus this week, compared to 2 articles on an average week.Search Interest4 people have searched for BVS on MarketBeat in the last 30 days. This is an increase of 33% compared to the previous 30 days. Company Ownership4.2 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Bioventus insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $512,511.00 in company stock.Percentage Held by Insiders32.90% of the stock of Bioventus is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.94% of the stock of Bioventus is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Bioventus' insider trading history. Receive BVS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Bioventus and its competitors with MarketBeat's FREE daily newsletter. Email Address BVS Stock News HeadlinesBioventus Inc. (NYSE:BVS) SVP Anthony D'adamio Sells 4,380 SharesFebruary 21, 2025 | insidertrades.comBioventus Inc. (NASDAQ:BVS) Q4 2024 Earnings Call TranscriptMarch 12, 2025 | msn.comYour Wealth is Under AttackHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's coming next. But here's the truth… This is just the beginning. Trump has made it clear his tariffs are coming, and that the market will get worse before it gets better. Luckily, our FREE Presidential Transition Guide details exactly what will happen in the next 100 days, and how to protect your hard-earned savings during these times. Don't wait for the next crash to wipe you out. Act now.March 17, 2025 | American Alternative (Ad)Bioventus Shares Rise After Improved 4QMarch 12, 2025 | marketwatch.comBioventus reports Q4 non-GAAP EPS 15c, consensus 8cMarch 12, 2025 | markets.businessinsider.comBioventus sees FY25 revenue $560M-$570M, consensus $554.78MMarch 12, 2025 | markets.businessinsider.comBioventus Inc. (BVS) Q4 2024 Earnings Call TranscriptMarch 11, 2025 | seekingalpha.comBioventus Announces Fourth Quarter and Full Year 2024 Financial ResultsMarch 11, 2025 | globenewswire.comSee More Headlines BVS Stock Analysis - Frequently Asked Questions How have BVS shares performed this year? Bioventus' stock was trading at $10.50 on January 1st, 2025. Since then, BVS shares have decreased by 6.7% and is now trading at $9.80. View the best growth stocks for 2025 here. How were Bioventus' earnings last quarter? Bioventus Inc. (NYSE:BVS) issued its quarterly earnings results on Tuesday, November, 5th. The company reported $0.06 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.06. The business had revenue of $138.96 million for the quarter, compared to analysts' expectations of $132.57 million. Bioventus had a positive trailing twelve-month return on equity of 15.61% and a negative net margin of 7.11%. When did Bioventus IPO? Bioventus (BVS) raised $126 million in an IPO on Thursday, February 11th 2021. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, J.P. Morgan, Goldman Sachs and Canaccord Genuity acted as the underwriters for the IPO. Who are Bioventus' major shareholders? Top institutional shareholders of Bioventus include Nantahala Capital Management LLC (4.96%), Vanguard Group Inc. (3.03%), Driehaus Capital Management LLC (1.38%) and American Century Companies Inc. (1.09%). Insiders that own company stock include John A Bartholdson, Juniper Investment Company, Ll, William A Hawkins, Anthony P Bihl III, Mark Leonard Singleton, Anthony D'adamio, John Nosenzo, Robert E Claypoole, Katrina J Church and Kenneth Michael Reali. View institutional ownership trends. How do I buy shares of Bioventus? Shares of BVS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Bioventus own? Based on aggregate information from My MarketBeat watchlists, some other companies that Bioventus investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), ServiceNow (NOW), Adobe (ADBE) and Arista Networks (ANET). Company Calendar Last Earnings11/05/2024Today3/17/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Surgical & medical instruments Sub-IndustryMedical Equipment Current SymbolNYSE:BVS CIK1665988 Webwww.bioventus.com Phone919-474-6700FaxN/AEmployees1,200Year FoundedN/APrice Target and Rating Average Stock Price Target$15.00 High Stock Price Target$17.00 Low Stock Price Target$13.00 Potential Upside/Downside+53.1%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.51) Trailing P/E RatioN/A Forward P/E Ratio23.90 P/E GrowthN/ANet Income$-156,230,000.00 Net Margins-7.11% Pretax Margin-10.41% Return on Equity15.61% Return on Assets4.01% Debt Debt-to-Equity Ratio1.85 Current Ratio1.41 Quick Ratio0.99 Sales & Book Value Annual Sales$573.28 million Price / Sales1.39 Cash Flow$0.78 per share Price / Cash Flow12.58 Book Value$2.80 per share Price / Book3.50Miscellaneous Outstanding Shares81,155,000Free Float54,455,000Market Cap$795.32 million OptionableNot Optionable Beta0.86 7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.Get This Free Report This page (NYSE:BVS) was last updated on 3/17/2025 by MarketBeat.com Staff From Our PartnersElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...American Hartford Gold | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHas Trump finally met his match?Dylan Jovine predicted the 2008 crash over a year before it happened. Folks who listened to him had the chance...Behind the Markets | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bioventus Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Bioventus With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.